Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
Sijan BasnetRashmi DhitalBiswaraj TharuPublished in: Medicina (Kaunas, Lithuania) (2019)
Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubulointerstitial nephritis on renal biopsy. Pembrolizumab was discontinued and the patient was started on long-term corticosteroids with a taper. Her renal function improved partially with treatment.
Keyphrases
- advanced non small cell lung cancer
- liver failure
- respiratory failure
- case report
- epidermal growth factor receptor
- single cell
- aortic dissection
- cell therapy
- stem cells
- emergency department
- intensive care unit
- adverse drug
- ultrasound guided
- bone marrow
- extracorporeal membrane oxygenation
- combination therapy
- tyrosine kinase
- mechanical ventilation
- diabetic nephropathy